Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 7584 results found since Jan 2013.
New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 2: Tapinarof
Skinmed. 2023 Aug 28;21(3):177-181. eCollection 2023.ABSTRACTSince its introduction in 1952, topical glucocorticosteroids remain the initial and long-term treatment option for various forms of inflammatory dermatitis. A number of non-steroidal topicals for treating inflammatory dermatoses have been developed in the recent decades (such as topical calcineurin inhibitors, vitamin D analogues, and phophodiesterase-4 inhibitors), but none had the combination of broad therapeutic range, relatively rapid onset of action, high tolerability, and wide-spread clinical success; this allowed topical glucocorticosteroids to remain the ...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Margaret DiRuggiero Elizabeth Mancuso-Stewart Douglas DiRuggiero Matt Zirwas Source Type: research
Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors
In this study, TPV/Δ66R/mIL-2 and TPV/Δ2L/Δ66R/FliC were tested for their ability to treat human melanoma xenografts (SK-MEL3) in a BALB/c nude mouse model reconstituted with splenocytes from genetically compatible, normal BALB/c donor mice. Two SK-MEL3 tumors were transplanted into each flank of BALB/c nude mice, and the larger tumor was treated intratumorally (IT) with virus or mock injection. In one set of animals, mice received adoptive transfers of splenocytes from BALB/c mice on day 4 to reconstitute their immune systems and allow for adaptive immune responses to occur in a xenograft model. Direct IT injection of ...
Source: Cancer Control - August 26, 2023 Category: Cancer & Oncology Authors: Michael L Monaco Omer A Idris Grace A Filpi Steven L Kohler Scott D Haller Jeffery E Burr Robert Eversole Karim Essani Source Type: research
Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus
Virology. 2023 Aug 10;587:109867. doi: 10.1016/j.virol.2023.109867. Online ahead of print.ABSTRACTLujo virus (LUJV), which belongs to Mammarenavirus, family Arenaviridae, has emerged as a pathogen causing severe hemorrhagic fever with high mortality. Currently, there are no effective treatments for arenaviruses, including LUJV. Here, we screened chemical compound libraries of Food and Drug Administration (FDA)-approved drugs and G protein-coupled receptor-associated drugs to identify effective antivirals against LUJV targeting cell entry using a vesicular stomatitis virus-based pseudotyped virus bearing the LUJV envelope g...
Source: Virology - August 26, 2023 Category: Virology Authors: Miyuki Kimura Risa Matsuoka Satoshi Taniguchi Junki Maruyama Slobodan Paessler Saori Oka Atsushi Yamashita Takasuke Fukuhara Yoshiharu Matsuura Hideki Tani Source Type: research
Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors
In this study, TPV/Δ66R/mIL-2 and TPV/Δ2L/Δ66R/FliC were tested for their ability to treat human melanoma xenografts (SK-MEL3) in a BALB/c nude mouse model reconstituted with splenocytes from genetically compatible, normal BALB/c donor mice. Two SK-MEL3 tumors were transplanted into each flank of BALB/c nude mice, and the larger tumor was treated intratumorally (IT) with virus or mock injection. In one set of animals, mice received adoptive transfers of splenocytes from BALB/c mice on day 4 to reconstitute their immune systems and allow for adaptive immune responses to occur in a xenograft model. Direct IT injection of ...
Source: Herpes - August 26, 2023 Category: Infectious Diseases Authors: Michael L Monaco Omer A Idris Grace A Filpi Steven L Kohler Scott D Haller Jeffery E Burr Robert Eversole Karim Essani Source Type: research
Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors
Blood Cells Mol Dis. 2023 Aug 17;104:102792. doi: 10.1016/j.bcmd.2023.102792. Online ahead of print.ABSTRACTSickle cell disease (SCD) is the most common β-hemoglobinopathy caused by various mutations in the adult β-globin gene resulting in sickle hemoglobin production, chronic hemolytic anemia, pain, and progressive organ damage. The best therapeutic strategies to manage the clinical symptoms of SCD is the induction of fetal hemoglobin (HbF) using chemical agents. At present, among the Food and Drug Administration-approved drugs to treat SCD, hydroxyurea is the only one proven to induce HbF protein synthesis, however, it...
Source: Blood Cells, Molecules and Diseases - August 26, 2023 Category: Hematology Authors: Chithra D Palani Xingguo Zhu Manickam Alagar Otis C Attucks Betty S Pace Source Type: research
Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus
Virology. 2023 Aug 10;587:109867. doi: 10.1016/j.virol.2023.109867. Online ahead of print.ABSTRACTLujo virus (LUJV), which belongs to Mammarenavirus, family Arenaviridae, has emerged as a pathogen causing severe hemorrhagic fever with high mortality. Currently, there are no effective treatments for arenaviruses, including LUJV. Here, we screened chemical compound libraries of Food and Drug Administration (FDA)-approved drugs and G protein-coupled receptor-associated drugs to identify effective antivirals against LUJV targeting cell entry using a vesicular stomatitis virus-based pseudotyped virus bearing the LUJV envelope g...
Source: Virology - August 26, 2023 Category: Virology Authors: Miyuki Kimura Risa Matsuoka Satoshi Taniguchi Junki Maruyama Slobodan Paessler Saori Oka Atsushi Yamashita Takasuke Fukuhara Yoshiharu Matsuura Hideki Tani Source Type: research
Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors
Blood Cells Mol Dis. 2023 Aug 17;104:102792. doi: 10.1016/j.bcmd.2023.102792. Online ahead of print.ABSTRACTSickle cell disease (SCD) is the most common β-hemoglobinopathy caused by various mutations in the adult β-globin gene resulting in sickle hemoglobin production, chronic hemolytic anemia, pain, and progressive organ damage. The best therapeutic strategies to manage the clinical symptoms of SCD is the induction of fetal hemoglobin (HbF) using chemical agents. At present, among the Food and Drug Administration-approved drugs to treat SCD, hydroxyurea is the only one proven to induce HbF protein synthesis, however, it...
Source: Blood Cells, Molecules and Diseases - August 26, 2023 Category: Hematology Authors: Chithra D Palani Xingguo Zhu Manickam Alagar Otis C Attucks Betty S Pace Source Type: research
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
This article summarizes key aspects of the regulatory review, including the indication statement, efficacy and safety considerations, and postmarketing requirements.PMID:37624619 | DOI:10.1158/1078-0432.CCR-23-1272
Source: Clinical Cancer Research - August 25, 2023 Category: Cancer & Oncology Authors: Deepti Telaraja Yvette L Kasamon Justin S Collazo Ruby Leong Kun Wang Ping Li Elyes Dahmane Yuching Yang Justin Earp Manuela Grimstein Lisa R Rodriguez Marc R Theoret Nicole J Gormley Source Type: research
